Breast Tumors: Clinical Trials

13 trials for Breast Tumors, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 4 terminated, 2 recruiting, 1 unknown. 13 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 213Completed 6, Terminated 4, Recruiting 2, Unknown 1
Phase 11Terminated 1

Follow Breast Tumors: new trials by email Literature Review of Breast Tumors trials Research Report on Breast Tumors

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Dalpiciclib, Pyrotinib, SHR-A1811 - Breast Neoplasm, Breast Cancer
Phase 2RecruitingFudan University7162022-11-012026-05-28
Therapeutic Dose Monitoring (TDM) of Tamoxifen
Tamoxifen 20 mg - Breast Cancer, Breast Carcinoma
Phase 2UnknownKarolinska University Hospital402022-04-042022-05-25
Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis
DS-8201a - Breast Tumors
Phase 2CompletedUNICANCER1862019-10-212025-06-12
Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
Paclitaxel, Alisertib - Breast Cancer, Breast Carcinoma
Phase 2CompletedUS Oncology Research1692015-02-122024-10-09
A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
Letrozole, palbociclib - Breast Cancer, Breast Carcinoma
Phase 2CompletedNSABP Foundation Inc3072015-01-012022-01-13
Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer
Metformin, Doxorubicin - Breast Cancer, Breast Tumors
Phase 2TerminatedAvera McKennan Hospital & University Health Center302014-07-012019-10-16
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Eribulin, Doxorubicin, Cyclophosphamide - Breast Neoplasms, Breast Cancer
Phase 2TerminatedEmory University72011-11-012016-10-03
Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors
Lapatinib - Brain Metastases, Lung Tumors
Phase 2CompletedHellenic Cooperative Oncology Group822010-10-012014-12-31
Re-expression of ER in Triple Negative Breast Cancers
Decitabine, LBH589, Tamoxifen - Breast Cancer, Breast Tumors
Phase 1 / Phase 2TerminatedEmory University52010-07-012015-01-26
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin - Breast Neoplasms, Breast Cancer
Phase 2RecruitingQuantumLeap Healthcare Collaborative50002010-03-012026-05-06
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
Pralatrexate Injection, Vitamin B12, Folic Acid - Breast Cancer, Breast Tumors
Phase 2CompletedAcrotech Biopharma Inc.222010-03-012020-01-07
QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer
AMG 479, Placebo - Breast Cancer, Breast Tumors
Phase 2CompletedNantCell, Inc.1562008-03-272024-09-19
A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer
AMG 706 placebo, Bevacizumab, AMG 706 - Breast Neoplasms, Breast Tumors
Phase 2TerminatedAmgen2822006-12-012015-10-15

Narrower conditions

Breast Neoplasms (13)  ·  Triple Negative Breast Neoplasms (3)  ·  Neoplasm Metastasis (2)  ·  Neoplasms (2)  ·  Brain Neoplasms (1)  ·  Cardiotoxicity (1)  ·  Hemangiosarcoma (1)  ·  Lung Neoplasms (1)  ·  Pathologic Complete Response (1)

Broader conditions

Breast Diseases (13)  ·  Neoplasms by Site (13)  ·  Skin Diseases (13)  ·  Skin and Connective Tissue Diseases (13)  ·  Neoplasms (11)  ·  Pathologic Processes (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Neoplastic Processes (2)  ·  Brain Diseases (1)  ·  Cardiovascular Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Central Nervous System Neoplasms (1)  ·  Chemically-Induced Disorders (1)  ·  Disease Attributes (1)  ·  Disease Progression (1)

Interventions

Paclitaxel (4)  ·  Doxorubicin (3)  ·  Letrozole (3)  ·  Carboplatin (2)  ·  Cyclophosphamide (2)  ·  Tamoxifen (2)  ·  Trastuzumab (2)  ·  ganitumab (2)  ·  pertuzumab (2)  ·  10-propargyl-10-deazaaminopterin (1)  ·  4-hydroxy-N-desmethyltamoxifen (1)  ·  ARX788 (1)  ·  Ado-Trastuzumab Emtansine (1)  ·  Albumin-Bound Paclitaxel (1)  ·  Bevacizumab (1)

Sponsors

Emory University (2)  ·  Acrotech Biopharma Inc. (1)  ·  Amgen (1)  ·  Avera McKennan Hospital & University Health Center (1)  ·  Fudan University (1)  ·  Hellenic Cooperative Oncology Group (1)  ·  Karolinska University Hospital (1)  ·  NSABP Foundation Inc (1)  ·  NantCell, Inc. (1)  ·  QuantumLeap Healthcare Collaborative (1)  ·  UNICANCER (1)  ·  US Oncology Research (1)

Countries

United States (8)  ·  France (3)  ·  Canada (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  China (1)  ·  Czechia (1)  ·  Germany (1)  ·  Greece (1)  ·  Hungary (1)  ·  Ireland (1)  ·  Spain (1)  ·  Sweden (1)  ·  Switzerland (1)

Top investigators

Christos Christodoulou, MD (1)  ·  Elham Hedayati, MD PhD (1)  ·  Garry Weems, PharmD (1)  ·  Joyce A. O'Shaughnessy, MD (1)  ·  Keerthi Gogineni, MD, MSHP (1)  ·  Kirstin Williams, CNP (1)  ·  Laura Esserman, MD, MBA (1)  ·  Norman Wolmark, MD (1)  ·  Ruth O'Regan, MD (1)  ·  Zhimin Shao, Professor (1)

Results publications

PMID 21429799, PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 27406346, PMID 27406347, PMID 28851423, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 33877311, PMID 34529000, PMID 34741021, PMID 35623341, PMID 35993306, PMID 36069821, PMID 36456573, PMID 37029329, PMID 37325931, PMID 37488289, PMID 37505107, PMID 38086377, PMID 38180338, PMID 38362377, PMID 38745646, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39405911, PMID 39613746, PMID 39625569, PMID 40526879, PMID 40551254, PMID 40639409, PMID 40679371, PMID 40777112, PMID 41879562, PMID 42530945, PMID 42545411, PMID 42619946, PMID 42811224

NIH funding

2008 (1), 2009 (1), 2018 (1)